• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Late complications of pancreas transplant

    2020-03-11 05:48:02JavierMaupoeyIbezAndreaBoscRobledoRafaelpezAndujar
    World Journal of Transplantation 2020年12期

    Javier Maupoey Ibá?ez, Andrea Boscà Robledo, Rafael López-Andujar

    Javier Maupoey Ibá?ez, Andrea Boscà Robledo, Rafael López-Andujar, Hepato-Pancreatico-Biliary Surgery and Transplant Unit, La Fe University Hospital, Valencia 46026, Spain

    Abstract To summarize the long-term complications after pancreas transplantation that affect graft function, a literature search was carried out on the long-term complications of pancreatic transplantation, namely, complications from postoperative 3rd mo onwards, in terms of loss of graft function, late infection and vascular complications as pseudoaneurysms. The most relevant reviews and studies were selected to obtain the current evidence on these topics. The definition of graft failure varies among different studies, so it is difficult to evaluate, a standardized definition is of utmost importance to know the magnitude of the problem in all worldwide series. Chronic rejection is the main cause of long-term graft failure, occurring in 10% of patients. From the 3rd mo of transplantation onwards, the main risk factor for late infections is immunosuppression, and patients have opportunistic infections like: Cytomegalovirus, hepatitis B and C viruses, Epstein-Barr virus and varicella-zoster virus; opportunistic bacteria, reactivation of latent infections as tuberculosis or fungal infections. Complete preoperative studies and serological tests should be made in all recipients to avoid these infections, adding perioperative prophylactic treatments when indicated. Pseudoaneurysm are uncommon, but one of the main causes of late bleeding, which can be fatal. The treatment should be performed with radiological endovascular approaches or open surgery in case of failure. Despite all therapeutic options for the complications mentioned above, transplantectomy is a necessary option in approximately 50% of relaparotomies, especially in lifethreatening complications. Late complications in pancreatic transplantation threatens long-term graft function. An exhaustive follow-up as well as a correct immunosuppression protocol are necessary for prevention.

    Key Words: Pancreas transplantation; Pancreas allograft failure; Pancreas transplant rejection; Pseudoaneurysm; Allograft pancreatectomy

    INTRODUCTION

    Pancreas transplantation is currently the most effective method to establish durable normoglycemia for patients with diabetes mellitus[1], and therefore achieves the benefits demonstrated with intensive insulin therapy, but without hypoglycemic complications derived from that treatment. Pancreatic graft loss may occur due to several complications, such as technical failure in the early postoperative period, but also late complications (which occur from postoperative 3rd mo onwards), among which the most relevant are chronic rejection, late infections and vascular complications as pseudoaneurysms. In recent years, pancreatic graft long-term survival has improved, with a half-life longer than 14 years in simultaneous pancreas and kidney (SPK) transplantation, which is the most frequent modality of pancreas transplantation as it is associated with better allograft survival[2]. In this review, we will describe the late complications of pancreas transplant and recent trends in their prevention, diagnosis and treatment.

    LOSS OF GRAFT FUNCTION

    The Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) Pancreas Transplantation Committee approved precise definitions of pancreas graft failure in early 2018. Some of the definitions are concrete, such as a recipient’s transplanted pancreas is removed, a recipient re-registers for pancreas transplant, a recipient registers for an islet transplant after undergoing pancreas transplant, or a recipient dies. Pancreas graft failure can also be defined if a recipient’s total insulin use is greater than or equal to 0.5 units/kg/d for a consecutive 90 d. The latter definition may be problematic if the recipient’s starting insulin dose is less than 0.5 units/kg/d[2].

    Recently the consensus report from the International Pancreas & Islet Transplant Association and European Pancreas & Islet Transplantation Association[3]defined the outcomes of beta–cell (b-cell) replacement therapy: Optimal b-cell graft function is defined by near-normal glycemic control (HbA1c ≤ 6.5% [48 mmol/mol]) without severe hypoglycemia or requirement for insulin or other antihyperglycemic therapy, and with an increase over pretransplant measurement of C-peptide. Good b-cell graft function requires HbA1c < 7.0% (53 mmol/mol) without severe hypoglycemia and with a significant (> 50%) reduction in insulin requirements and restoration of clinically significant C-peptide production. Marginal b-cell graft function is defined by failure to achieve HbA1c < 7.0% (53 mmol/mol), the occurrence of any severe hypoglycemia, or less than 50% reduction in insulin requirements when there is restoration of clinically significant C-peptide production documented by improvement in hypoglycemia awareness/severity, or glycemic variability/lability. A failed b-cell graft is defined by the absence of any evidence for clinically significant C-peptide production. Optimal and good functional outcomes are considered successful clinical outcomes.

    Although these newer definitions have not yet been reflected, reported early overall rate of pancreas graft failure (within the first 90 d) in 2018 was 5.9%, and 5-year pancreas graft survival rates were 73% for SPK, 65% for pancreas after kidney (PAK), and 53% for pancreas transplant alone (PTA)[2]. These results are similar in Spain, with a 5-year graft survival rate of 72%-74% for SPK[4].

    Adverse technical and immunological events within the 1styear need to be avoided under all circumstances; what happens in the 1styear posttransplant has a very strong impact on long-term graft function[5]. The main cause of pancreas graft loss within the first 3 mo usually is technical failure: Graft thrombosis (10%-35%) followed by intraabdominal infections and pancreatitis[6]. An adequate immunosuppression therapy with tight control is recommended to avoid pancreas allograft rejection, since it is also one of the main causes of graft failure. Acute rejection usually develops 1 wk to 3 mo after transplantation but can occur earlier or later, it is difficult to diagnose, but may be suspected when loss of allograft function (hyperglycemia) is associated with high level of serum amylase and/orlipase. Early detection is essential to institute antirejection treatment and avert graft failure. Incidence in OPTN/UNOS data of a first rejection episode is improving over time, with low rates respect previous data for all categories of pancreas transplant, in 2016-2017 in the United States it was: 11.7%, 19.2%, and 12.4% following PAK, PTA and SPK respectively[2]. In the same way, global incidence of rejection in Spain series was 10.9% in SPK during last decade[4]. These low rejection rates clearly reflect ongoing improvements in immunosuppression protocols. In fact, the avoidance of acute rejection episodes is probably the single highest impact on excellent long-term function[5].

    There is some controversy regarding immunosuppressive treatment in pancreas transplantation. Standard protocols include use of induction therapy followed by maintenance immunosuppression, but the amount, frequency and duration of each therapy, especially the induction treatment has not been clearly defined, which consist in T-cell depleting agent (e.g., antithymocyte globulin and alemtuzumab), even though it has been adopted by most centers (> 80%). Maintenance immunosuppressive therapy for pancreatic transplantation is similar for that used for kidney transplantation. A combination of a calcineurin inhibitor (predominantly tacrolimus), an antimetabolite (mycophenolate mofetil or mycophenolate sodium), is associated to low-dose corticosteroids therapy in approximately 60% of the centers[2]. However, taking into account the metabolic side effects as well as the increased risk of infection associated with the use of steroids[7], some studies have suggested early steroid withdrawal or steroid free regimens in these patients, particularly after the introduction of induction therapy with T-cell depleting agents, but there is currently insufficient evidence for the benefits and harmsof this therapy[8]. There is also a trend to incorporate mammalian target of rapamycin (mTOR) inhibitors over mycophenolate in combination with tacrolimus into immunosuppressive protocol, because rapamycin appears to be more effective in preventing acute rejection, but it must be weighed against its potential negative metabolic consequences and the accentuation of the nephrotoxicity of the calcineurin inhibitor and wound-healing complications[9-11], so at the moment it has not been widely adopted. Future research should focus on developing personalized immune assessment of transplant patients, through noninvasive tests of immunological biomarkers to monitor the recipient’s immune status[12]. These tests will permit recipient-specific tailored immunosuppressive protocols, based on their immunity response and individual risk, minimizing the complications of excessive immunosuppression while maintaining a low incidence of rejection.

    Chronic rejection remains the main cause of long-term graft failure after 1 year, occurring in 10% of patients[13,14]. It may be the result of recurrent episodes of acute rejection with posterior fibrosis, atrophy, and eventual loss of graft function. Therefore, effective immunosuppression protocols and close monitoring of pancreas and kidney allograft function are the best way to prevent it. The image tests findings of acute and chronic rejections are relatively nonspecific and unreliable, making it difficult to diagnose[15]. Diagnostic confirmation must be performed by needle core pancreas allograft biopsy, preferably percutaneous ultrasound-guided biopsy[16]. The Banff schema for grading pancreas allograft rejection based on pathological findings, differentiate the type (T-cell-mediated rejection or antibody-mediated pancreas allograft rejection) and the grade (mild, moderate, and severe) with a high diagnostic accuracy, helping to select the appropriate treatment in each case[17,18].

    Given the possibility of chronic rejection, type 1 diabetes mellitus recurrence should also be suspected, which is an infrequent entity, appearing approximately in 3%-7% of properly immunosuppressed patients[19]. It occurs due to the presence of antibodies against pancreatic beta cells in the recipient (type 1 diabetes-associated autoantibodies to the autoantigens GAD65, IA-2, and ZnT8) causing destruction of the pancreatic islets (insulitis). Usually the antibody conversion precede hyperglycemia by a variable length of time, and negative autoimmunity prior to transplantation does not ensure that autoimmune diabetes will not recur. Unlike rejection, serum amylase and lipase levels usually do not rise, and there is no effective treatment, as the increase in immunosuppression does not improve the progression of islet autoimmunity. Diagnostic confirmation must be performed by percutaneous biopsy, in which a variable degree of insulitis and loss of insulin staining must be seen, sometimes associated to minimal to moderate and rarely severe pancreas and/or kidney transplant rejection[20].

    The 5-year mortality for SPK in OPTN/UNOS data[2]and Spanish series[4]ranges over 7% to 8%. Long-term mortality data reflect the high cardiovascular comorbidity in this population, with 10-year mortality 26.8%, 20.1%, and 25.3% for PAK, PTA, and SPK, respectively. Despite effective glycemia control after pancreas transplantation delays progression of microvascular complications and improves survival in diabetic patients, cardiovascular comorbidity is the main factor that threatens long-term survival of pancreas transplant patients[5], so its optimal control is another of the priority objectives in the follow up of this patients.

    There has been controversy regarding transplant center volume and the risk of short and long-term pancreas graft failure, so it has been analyzed by several studies, highlighting that patient and graft survival after pancreas transplantation are superior in higher volume centers (> 13 transplants/year) than in lower volume centers[21,22], or at least equal even though they transplant organs with the highest pancreas donor risk index[23]. The explanation for inferior outcomes in low-volume centers is likely to be complex, but center volume could be a surrogate marker for adequate recipient selection, surgical expertise, multidisciplinary preoperative, and postoperative inpatient and outpatient care, and appropriate long-term follow-up. Actually, approximately two-thirds of pancreas transplants are performed at programs that perform more than 10 transplants per year, and these numbers have not changed substantially over the past decade[2], this may have contributed to explain the improvement of global pancreas allograft and patient survival throughout last years, demonstrating a better management in these demanding patients over time.

    CHRONIC INFECTION

    Approximately 63% of pancreas transplant recipients develop a serious infection during the first 5 years of follow-up[24]. Many of the infections in pancreas transplantation follow a typical temporal pattern. Three periods have been described based on the predominance of certain infections: In the first period (1stmo), bacterial infections derived from the surgical procedure are typical. In the second period (2-6 mo), the main risk factor is immunosuppression, and patients basically have de novo opportunistic infections or reactivation of latent diseases: Cytomegalovirus (CMV), herpes simplex virus type 6 (VHV), hepatitis B and C viruses (HBV/HCV), Epstein-Barr virus (EBV) and varicella-zoster virus (VZV); and opportunistic bacteria:Pneumocystis jirovecipneumonia, Nocardia, Listeria monocytogenes,Toxoplasma gondii, and fungal infections, among others. During the third period (after the 6thmo), in patients with good allograft function, the majority of infections are those acquired in the community, similar to the general population, although opportunistic infections may also occur, by reactivation of certain latent viruses (BK virus, CMV…)[7]. In addition, tumors related to viral infections such as vulgar warts and post-transplant lymphoproliferative diseases, especially due to EBV, may develop in this period[25].

    Prevention of infections

    Prophylaxis before transplant:Prevention of infection begins with the adequate selection of the donor and a rigorous evaluation of the recipient with an exhaustive physical examination and study of viral serological markers: CMV, EBV, VZV, HBV, HCV, HIV toxoplasmosis,Treponema pallidumserology, and some others that can vary according to the epidemiology of each geographic area. This permits us to diagnose and treat active infections in the candidates, make decisions about their acceptance or exclusion, and identify the risk factors. Moreover, vaccinations must be completed before the transplantation according to the protocol of each center and geographical area[24].

    Perioperative prophylaxis:At the time of the transplant surgery, prophylactic administration of antibiotics like cephalosporins, or ampicillin-sulbactam as an alternative, every 2 h during surgery, and maintenance until 48 h after surgery is recommended. Antifungals (fluconazole) are also associated in a single dose during surgery, and in postoperative prophylaxis regimen up to 14 d in cases of increased risk of infection[26]. The choice of therapeutic agent, both for prophylaxis and for empirical treatment, will also depend on the incidence and type of microorganisms isolated in each center.

    The use of cotrimoxazole at low doses until the 6thmo post-transplant has decreased the incidence ofPneumocystis pneumonia[27]. Likewise, it constitutes an excellent prophylaxis to avoid infection by intracellular bacteria, such asListeria monocytogenesandNocardia spp.

    CMV prophylaxis and monitoring after transplantation:CMV infections are one of the most frequent complications affecting solid organ transplant recipients, conveying higher risk of graft loss, morbidity and mortality. Given that the CMV serostatus of donor and recipient (D/R) are key predictors of the risk of CMV after transplant, and guide decisions on antiviral prophylaxis or preemptive treatment. A measurement of CMV-specific IgG should be performed, and if the donor or recipient is seronegative during the pretransplant evaluation, serology should be repeated at the time of the transplantation. According to the guidelines of the latest international consensus of 2018 on the management of CMV in solid organ transplants[28], in pancreas transplantation, prophylactic treatment with valganciclovir is recommended based on the risk of CMV infection (Table 1). Other valid option is the preemptive therapy, which consists in the monitoring of CMV viral load in blood at regular intervals (weekly) to detect early viral replication. Once a predetermined assay threshold is achieved (optimally prior to the development of symptoms), antiviral treatment is begun, which should prevent progression to clinical disease. Moreover, there are specific situations that increase the risk of CMV infection, such as in cases where antilymphocyte antibodies for induction are administered, plasmapheresis or HIV infection patients. In these cases, it is also mandatory to administer a prophylactic treatment with valganciclovir, and duration will depend on the degree of immunosuppression of the patient. However, there are resistances associated with currently available therapeutics, as there are series with pancreas-kidney transplant high risk patients (D+/R-) who developed CMV infection/disease despite correct CMV prophylaxis in up to 44%[29]. Novel antivirals therapies are emerging including letermovir, maribavir, and brincidofovir at various states of research development. Future research are needed to evaluate combination therapies for prophylaxis and treatment as well as adjunctive therapies[30].

    Furthermore, there is moderate to high-quality evidence of a lower risk of CMV infection in transplant recipients with mTOR inhibitor-based immunosuppressive therapy compared with calcineurin inhibitor-based regimens, therefore a combination of a mTOR inhibitor and a reduced dose of calcineurin inhibitor could be a good alternative in high risk CMV infection patients[31,32].

    Prevention of tuberculosis infection:In the pre-transplant evaluation, the possibility of latent tuberculosis infection should be assessed by performing the tuberculin skin test (TST), and/or tests based on the secretion of interferon gamma by memory T cells in response to mycobacterial antigens (interferon gamma release assays) as QuantiFERON TM-TB Gold test. If the result is positive in any of these tests, a prophylactic treatment with isoniazid should be administered, and active tuberculosis infection should also be ruled out. If tuberculosis infection is confirmed, the transplant would be contraindicated until the infection is cured.

    According to the guidelines of the European Society for Clinical Microbiology and Infectious Diseases[33], if the TST or QuantiFERON are positive, or the chest X-ray shows lesions of previous tuberculosis, and there is no evidence that the patient have received a correct treatment, chemoprophylaxis with isoniazid for 9 mo should be administered.

    PSEUDOANEURYSM

    Pseudoaneurysms (PA) occur due to a laceration or disruption of the arterial wall caused by chemical damage due to the exposure to enzymes in the event of pancreatic fistulas or infections with peripancreatic collections, chronic rejections, surgical trauma or biopsies, causing a bleeding into an external fibrous compartment that will contain the hematoma. Vascular anastomoses are the most frequent areas affected by PA, but those caused by biopsies usually occur in the pancreatic parenchyma, and can lead to arteriovenous fistulas.

    Table 1 Recommended approaches for cytomegalovirus prevention for adult pancreas transplant

    Although PA are infrequent entities, they are one of the main causes of late bleeding, sometimes years after transplantation, which can be lethal. PA tend to debut first with mild digestive hemorrhages, called sentinel bleeding, which can progress to an arteriovenous or arterioenteric fistula[34], preceding of fatal hemorrhage. PA are difficult to detect before the development of massive hemorrhage due to the absence or mildness of the previous symptoms. For this reason, graft control with doppler ultrasonography in the follow up should be performed[35]. Once PA is suspected or demonstrated at ultrasonography, the full anatomy of the PA is best displayed with volumetric high-spatial-resolution CT scanning (angio-CT) or magnetic resonance angiography[14]. Such imaging display is required before planning the treatment (Figure 1).

    Current treatment of PA firstly should be performed with radiological endovascular approaches, when possible. Although there is still a lack of reliable data due to the relatively little experience of this approach in pancreas transplant complications, endovascular procedures are becoming more frequently used as they are safe and feasible, but technically demanding. One of the main risks of this approach is the renal function damage caused by contrast agent, but the risk of kidney graft function deterioration, as well as of bleeding due to the high dose of heparin used, seems to be lower than with open surgery[36].

    When a PA is diagnosed, elective treatment should be performed to prevent the potential life- and graft-threatening bleeding. The choice between minimally invasive and open surgical repair should be individualized depending on the site of the lesion, the patient status and the multidisciplinary team experience[37,38]. Nevertheless, at the time of acute bleeding, immediate treatment is essential: Endovascular approach with a covered stenting of the involved artery to exclude the PA may provide immediate vascular control in these situations. But if an arteriovenous fistula exists, embolization with microparticles is the treatment of choice[39]. These procedures can be either a definitive treatment[40]or a bridge therapy to posterior open repair[41,42], since rebleeding or necrosis and posterior loss of graft function are not uncommon. For this reason, on many occasions (especially in infections) allograft transplantectomy including the graft vascular anastomosis is performed, requiring sometimes an extra anatomic bypass to maintain blood flow of the lower limb[43].

    ALLOGRAFT PANCREATECTOMY: INDICATIONS AND SURGICAL TECHNIQUE

    Indications

    Surgical complications after pancreas transplantation and later relaparotomies are frequent (25%-30%) and the main cause are thrombosis, bleeding, infection, pancreatitis and bowel obstruction. Unfortunately, it implies allograft pancreatectomy in 50% of cases, and occasionally patient death[44]. The management of such complications has evolved from a low threshold to remove the graft, to considering options for graft preservation through the new antimicrobial and immunosuppressive therapies, as well as the imaging techniques that permit an early diagnosis and imageguided invasive procedures. However, the need to perform a transplantectomy is a necessary situation in some occasions, especially in life-threatening complications. Currently there are no guidelines or consensus that clearly indicate to the surgeon when and how it should be performed, but as a general rule, safety of the recipient should be considered as the main factor to take into account.

    Figure 1 Pseudoaneurysm in the right iliac artery anastomosis of the pancreas graft in a simultaneous pancreas and kidney patient (arrows).

    Thrombosis-related graft necrosis, severe pancreatitis, and uncontrolled duodenal leak constitute the main indications for allograft pancreatectomy during the first 4 wk after transplantation[44]. And late allograft pancreatectomy is usually reserved for recipients with failed grafts, predominantly from chronic rejection who have abdominal and flank pain, gastrointestinal symptoms and/or fever[45]. The rate of allograft pancreatectomy for late graft failure ranges from 25% to 50%, and in these cases the symptoms associated with the failed pancreas graft, risk of formation of arterioenteric fistula, and candidacy for potential retransplantation need to be cautiously evaluated in order to appropriately select the timing and the surgical approach for allograft pancreatectomy[46]. Recent studies show a marked fall in morbidity and mortality of allograft pancreatectomy, and emphasize the benefits of early retransplantation in appropriate candidates[47]. However, late pancreas retransplantation is also possible, although it has been associated with poorer allograft survival[48], in recent series technical failure and patient death for primaryvspancreas retransplants are similar in highly selected patients, if they are carried out in experienced centers[49-51].

    Surgical technique

    In cases of early transplantectomy, adhesions are not usually a problem. In order to gain rapid exposure of the vascular anastomoses, it is helpful to divide the enteric anastomosis first using a gastrointestinal anastomosis stapler by resecting the jejunum segment together with the duodenum (in enteric drainage transplants). The portal vein and iliac artery of the graft are clamped, divided, and oversewn. And then, the intestinal transit is reestablished with a jejunal anastomosis.

    In cases of late transplantectomy, it can be performed in isolation or associated with a pancreas retransplantation. The operative field can be complex due to the adhesions, and in many occasions the graft will be shrunken, fibrosed, and poorly perfused, and there may be extensive adhesions to the retroperitoneum, making it difficult to identify. When graft pancreatectomy is performed as an isolated operation, the complete exposure of the recipient vasculature is often unnecessary. But when a failed allograft is removed at the time of retransplantation, the initial pancreas graft must be carefully explored and dissected away from the recipient iliac vessels and the inferior vena cava, in order to identify appropriate sites for implantation of the new pancreas graft. The allograft portal vein and iliac artery, once identified, are divided and oversewn taking care to avoid compromising the recipient arterial lumen. In cases where is not possible to preserve the recipient iliac vessels blood flow due to their involvement, as in PA or arterioenteric fistulas, an endovascular placement of a covered stent can be placed at the level of the anastomotic site. Alternatively, if it is not effective, an angioplasty with bovine pericardial patch can be done in cases of small defects of the vessel wall. Otherwise, a reconstruction with a synthetic prosthesis or cadaver graft if available in cases of major vessel damage is a valid option[52].

    CONCLUSION

    Pancreas transplantation is a complex and technically demanding procedure. Early complications may occur, mostly due to technical failure as thrombosis, intraabdominal infections and pancreatitis. But late complications also entail a high percentage of graft losses, particularly secondary to chronic rejection or even late infections. PA are uncommon, but one of the main causes of late bleeding, which can be fatal. A high index of suspicion is needed to detect it, and once PA is diagnosed, the treatment should be performed, preferably with radiological endovascular approaches or open surgery in case of failure. Despite all therapeutic options for the complications mentioned above, transplantectomy is necessary in approximately 50% of relaparotomies, especially in life-threatening complications. Although pancreas retransplantation can be performed later in selected patients. Close monitoring of graft function and clinical and radiological surveillance, as well as new advances in the immunosuppression protocols, individualized according to the patient′s situation are crucial to prevent rejection, improving pancreas graft survival, as well as the optimal control of cardiovascular comorbidity to achieve better patient long-term survival.

    国产xxxxx性猛交| 亚洲人成电影免费在线| 午夜成年电影在线免费观看| 777久久人妻少妇嫩草av网站| 午夜福利视频在线观看免费| 大香蕉久久网| 久久香蕉激情| 少妇猛男粗大的猛烈进出视频| 亚洲三区欧美一区| 亚洲成人国产一区在线观看| 久久精品亚洲av国产电影网| 国产人伦9x9x在线观看| 黄色成人免费大全| 国产精品香港三级国产av潘金莲| 亚洲一码二码三码区别大吗| www.精华液| 欧美性长视频在线观看| 精品国产一区二区三区四区第35| 少妇裸体淫交视频免费看高清 | 大型av网站在线播放| 亚洲欧美激情综合另类| 美女福利国产在线| 国产深夜福利视频在线观看| 国产精品.久久久| 国产av又大| 国产aⅴ精品一区二区三区波| 下体分泌物呈黄色| 亚洲成人国产一区在线观看| 一区在线观看完整版| 精品第一国产精品| 久久久精品区二区三区| 亚洲精品一二三| 国产成人精品久久二区二区91| 亚洲一区高清亚洲精品| 搡老熟女国产l中国老女人| 天天躁夜夜躁狠狠躁躁| 精品久久久久久久毛片微露脸| 人人澡人人妻人| 午夜两性在线视频| 亚洲第一青青草原| 波多野结衣一区麻豆| 欧美久久黑人一区二区| 亚洲五月色婷婷综合| av欧美777| 精品免费久久久久久久清纯 | 日韩欧美一区视频在线观看| 99riav亚洲国产免费| 夫妻午夜视频| 天堂俺去俺来也www色官网| 国产精品国产av在线观看| av网站免费在线观看视频| 成人三级做爰电影| 久久香蕉精品热| 国产精品免费一区二区三区在线 | 亚洲va日本ⅴa欧美va伊人久久| 精品亚洲成a人片在线观看| 91精品三级在线观看| 成人黄色视频免费在线看| 精品一区二区三区av网在线观看| 国产欧美日韩一区二区三区在线| 免费高清在线观看日韩| 99久久综合精品五月天人人| 国产精品1区2区在线观看. | 多毛熟女@视频| 老司机在亚洲福利影院| 黄片小视频在线播放| 国产成人影院久久av| 午夜成年电影在线免费观看| 婷婷成人精品国产| 国产成人精品在线电影| 精品欧美一区二区三区在线| 下体分泌物呈黄色| 亚洲精品美女久久久久99蜜臀| 久久性视频一级片| 王馨瑶露胸无遮挡在线观看| 国产又爽黄色视频| 中亚洲国语对白在线视频| 午夜成年电影在线免费观看| 黄网站色视频无遮挡免费观看| 亚洲成人国产一区在线观看| 在线观看免费午夜福利视频| 国产亚洲精品一区二区www | 亚洲精品av麻豆狂野| 久久久久久人人人人人| 亚洲av第一区精品v没综合| 亚洲免费av在线视频| 热re99久久国产66热| 999久久久国产精品视频| 老汉色av国产亚洲站长工具| 99久久精品国产亚洲精品| 精品久久久精品久久久| 国产不卡一卡二| 亚洲aⅴ乱码一区二区在线播放 | 亚洲专区字幕在线| 国产蜜桃级精品一区二区三区 | 999久久久国产精品视频| 午夜福利在线免费观看网站| 大片电影免费在线观看免费| 在线观看www视频免费| 高清视频免费观看一区二区| 国产成人av教育| 美女福利国产在线| 午夜福利乱码中文字幕| 欧美色视频一区免费| 啦啦啦在线免费观看视频4| 人人妻,人人澡人人爽秒播| 久久中文字幕人妻熟女| 国产精品久久电影中文字幕 | 满18在线观看网站| 国产高清国产精品国产三级| 91字幕亚洲| 天天添夜夜摸| 色尼玛亚洲综合影院| 亚洲熟女毛片儿| 中文字幕人妻丝袜一区二区| 国产区一区二久久| 中文亚洲av片在线观看爽 | 欧美乱码精品一区二区三区| 亚洲第一av免费看| 成年人黄色毛片网站| 91精品国产国语对白视频| 99国产极品粉嫩在线观看| 精品国产乱码久久久久久男人| 欧美日韩亚洲国产一区二区在线观看 | 一级毛片精品| 成年动漫av网址| 日韩大码丰满熟妇| 高潮久久久久久久久久久不卡| 一进一出抽搐gif免费好疼 | 最新在线观看一区二区三区| 国产精品免费视频内射| 久久久久久久午夜电影 | av国产精品久久久久影院| 日韩中文字幕欧美一区二区| 欧美黄色片欧美黄色片| 日本wwww免费看| 中文字幕精品免费在线观看视频| 在线免费观看的www视频| 午夜福利在线观看吧| xxx96com| 一级a爱片免费观看的视频| av超薄肉色丝袜交足视频| 两个人看的免费小视频| 国产野战对白在线观看| 十八禁人妻一区二区| 亚洲精品久久午夜乱码| videos熟女内射| 久久久久久久精品吃奶| av国产精品久久久久影院| videos熟女内射| 老鸭窝网址在线观看| 亚洲情色 制服丝袜| 久久久久久久国产电影| 交换朋友夫妻互换小说| 啦啦啦在线免费观看视频4| 久久国产乱子伦精品免费另类| 51午夜福利影视在线观看| 国产精品永久免费网站| 久久精品国产a三级三级三级| 日本a在线网址| 高清av免费在线| 一边摸一边抽搐一进一出视频| 欧美午夜高清在线| 日韩一卡2卡3卡4卡2021年| 热99国产精品久久久久久7| av视频免费观看在线观看| 99香蕉大伊视频| 香蕉久久夜色| 99国产精品免费福利视频| 亚洲国产精品一区二区三区在线| 精品一区二区三区av网在线观看| 久久国产精品男人的天堂亚洲| 国产黄色免费在线视频| 欧美乱码精品一区二区三区| 日本精品一区二区三区蜜桃| 久久久国产成人精品二区 | 在线永久观看黄色视频| 在线观看免费午夜福利视频| 精品福利观看| 亚洲av日韩精品久久久久久密| 日本vs欧美在线观看视频| 国产亚洲精品一区二区www | 一区二区三区国产精品乱码| 久热这里只有精品99| 69精品国产乱码久久久| 精品福利观看| 91成年电影在线观看| 一级片'在线观看视频| 老司机靠b影院| 久久中文字幕一级| 最新美女视频免费是黄的| 伊人久久大香线蕉亚洲五| 免费女性裸体啪啪无遮挡网站| 国产精品欧美亚洲77777| 悠悠久久av| 国产亚洲精品久久久久5区| 国产精品 欧美亚洲| 超碰97精品在线观看| 午夜福利在线免费观看网站| 亚洲情色 制服丝袜| 精品人妻1区二区| 精品福利永久在线观看| 好看av亚洲va欧美ⅴa在| 欧美在线黄色| 久9热在线精品视频| 高清欧美精品videossex| 丰满的人妻完整版| 99久久精品国产亚洲精品| 一级a爱视频在线免费观看| 啦啦啦 在线观看视频| 狂野欧美激情性xxxx| 成人特级黄色片久久久久久久| 久久国产精品大桥未久av| 午夜久久久在线观看| 每晚都被弄得嗷嗷叫到高潮| 中国美女看黄片| 在线国产一区二区在线| 亚洲男人天堂网一区| 最新在线观看一区二区三区| 欧美日韩亚洲高清精品| 麻豆av在线久日| 亚洲av片天天在线观看| 在线免费观看的www视频| 国产成人免费观看mmmm| 999久久久国产精品视频| 精品福利永久在线观看| 午夜91福利影院| 午夜福利一区二区在线看| 人人妻人人澡人人看| 亚洲一区中文字幕在线| 成人亚洲精品一区在线观看| 国产aⅴ精品一区二区三区波| 女人高潮潮喷娇喘18禁视频| 久久香蕉激情| 热re99久久精品国产66热6| 欧美日韩乱码在线| 国产99久久九九免费精品| 波多野结衣av一区二区av| 交换朋友夫妻互换小说| 一区二区三区精品91| 国产一区二区三区综合在线观看| 免费高清在线观看日韩| x7x7x7水蜜桃| 精品久久久精品久久久| 伊人久久大香线蕉亚洲五| 国产男女超爽视频在线观看| 国产97色在线日韩免费| 黑人欧美特级aaaaaa片| 丝袜在线中文字幕| 久久香蕉国产精品| 99久久精品国产亚洲精品| 美国免费a级毛片| 老熟妇仑乱视频hdxx| 国产精品二区激情视频| 久久99一区二区三区| 狂野欧美激情性xxxx| 欧美国产精品va在线观看不卡| 丁香欧美五月| 亚洲黑人精品在线| 国产精品 欧美亚洲| 妹子高潮喷水视频| 91精品三级在线观看| 极品人妻少妇av视频| 国产成+人综合+亚洲专区| 欧洲精品卡2卡3卡4卡5卡区| 国产成人精品无人区| 黄色怎么调成土黄色| 啦啦啦免费观看视频1| 超色免费av| 国产成人精品久久二区二区免费| 99re在线观看精品视频| 亚洲人成电影观看| 91精品国产国语对白视频| 无遮挡黄片免费观看| 久久99一区二区三区| 黄色毛片三级朝国网站| 国产精品国产av在线观看| 少妇的丰满在线观看| 久久人人97超碰香蕉20202| 最新的欧美精品一区二区| 亚洲自偷自拍图片 自拍| 亚洲中文av在线| 国产精品一区二区在线不卡| 精品视频人人做人人爽| 色综合欧美亚洲国产小说| 自线自在国产av| 十八禁人妻一区二区| 激情在线观看视频在线高清 | 精品久久久久久久久久免费视频 | 十八禁网站免费在线| 丰满人妻熟妇乱又伦精品不卡| 天天躁狠狠躁夜夜躁狠狠躁| av片东京热男人的天堂| 久久久久久久国产电影| 99热国产这里只有精品6| 国产亚洲av高清不卡| 天天操日日干夜夜撸| 亚洲欧美一区二区三区久久| 久久精品人人爽人人爽视色| 中文字幕av电影在线播放| 深夜精品福利| 丰满人妻熟妇乱又伦精品不卡| 久久久国产欧美日韩av| 欧美在线一区亚洲| 操美女的视频在线观看| 黄片大片在线免费观看| 亚洲情色 制服丝袜| 免费在线观看影片大全网站| 露出奶头的视频| 91麻豆av在线| 亚洲欧美一区二区三区久久| tube8黄色片| 久久中文字幕一级| 亚洲一区二区三区不卡视频| 精品国产乱码久久久久久男人| 啦啦啦在线免费观看视频4| 国产99白浆流出| 国产免费现黄频在线看| 黄色片一级片一级黄色片| 免费一级毛片在线播放高清视频 | 男人的好看免费观看在线视频 | 亚洲色图综合在线观看| videos熟女内射| 中文字幕人妻丝袜制服| 免费av中文字幕在线| 精品国产亚洲在线| 99精品欧美一区二区三区四区| 国产色视频综合| 岛国在线观看网站| 性色av乱码一区二区三区2| 中文字幕高清在线视频| 老司机影院毛片| 一级毛片高清免费大全| 女人久久www免费人成看片| 亚洲欧洲精品一区二区精品久久久| 啦啦啦免费观看视频1| 久久久国产成人精品二区 | 国产有黄有色有爽视频| 亚洲自偷自拍图片 自拍| 99国产综合亚洲精品| 精品卡一卡二卡四卡免费| 19禁男女啪啪无遮挡网站| 一级毛片女人18水好多| 欧美日本中文国产一区发布| 久久 成人 亚洲| 亚洲av成人av| 啦啦啦视频在线资源免费观看| 19禁男女啪啪无遮挡网站| 免费观看精品视频网站| 亚洲av成人av| 真人做人爱边吃奶动态| 久久国产精品大桥未久av| 看片在线看免费视频| 午夜福利欧美成人| 日韩一卡2卡3卡4卡2021年| 日韩制服丝袜自拍偷拍| 成年人黄色毛片网站| 高清欧美精品videossex| 黑丝袜美女国产一区| 男男h啪啪无遮挡| 久久精品人人爽人人爽视色| 搡老熟女国产l中国老女人| 黄色视频,在线免费观看| 中文字幕高清在线视频| 99国产综合亚洲精品| 好看av亚洲va欧美ⅴa在| 国产av精品麻豆| 色播在线永久视频| 免费观看人在逋| 91九色精品人成在线观看| 精品国产一区二区三区久久久樱花| 亚洲中文日韩欧美视频| 香蕉丝袜av| 香蕉久久夜色| 久久99一区二区三区| 欧美不卡视频在线免费观看 | 最新美女视频免费是黄的| 国产精品免费一区二区三区在线 | 欧美黑人精品巨大| www.熟女人妻精品国产| 久久中文看片网| 久久午夜综合久久蜜桃| 捣出白浆h1v1| 亚洲av成人一区二区三| 91精品三级在线观看| 亚洲成国产人片在线观看| 嫁个100分男人电影在线观看| 十分钟在线观看高清视频www| av不卡在线播放| 日本欧美视频一区| 天天操日日干夜夜撸| 男女高潮啪啪啪动态图| 热re99久久精品国产66热6| 精品免费久久久久久久清纯 | 一二三四在线观看免费中文在| 99在线人妻在线中文字幕 | 国产亚洲精品第一综合不卡| 婷婷丁香在线五月| 他把我摸到了高潮在线观看| 亚洲欧美日韩高清在线视频| 国产免费现黄频在线看| 免费在线观看视频国产中文字幕亚洲| а√天堂www在线а√下载 | 亚洲一卡2卡3卡4卡5卡精品中文| 女人被躁到高潮嗷嗷叫费观| 精品国产一区二区久久| 午夜福利视频在线观看免费| 国产成人啪精品午夜网站| 一区二区日韩欧美中文字幕| 精品第一国产精品| 国产一区二区三区综合在线观看| 精品高清国产在线一区| 天天添夜夜摸| 欧美不卡视频在线免费观看 | xxx96com| 日韩熟女老妇一区二区性免费视频| 窝窝影院91人妻| 久久香蕉国产精品| 国产亚洲精品一区二区www | 日本黄色视频三级网站网址 | 日韩成人在线观看一区二区三区| 多毛熟女@视频| 99热只有精品国产| 精品国内亚洲2022精品成人 | 一级片'在线观看视频| av欧美777| 伦理电影免费视频| 亚洲精品国产精品久久久不卡| 一区二区三区国产精品乱码| 国产午夜精品久久久久久| 久久 成人 亚洲| 久久中文字幕人妻熟女| 久久精品亚洲精品国产色婷小说| 亚洲国产精品一区二区三区在线| 中文亚洲av片在线观看爽 | 波多野结衣av一区二区av| 欧美日韩亚洲国产一区二区在线观看 | 亚洲人成77777在线视频| 国产亚洲精品一区二区www | 男人舔女人的私密视频| 久久久久久亚洲精品国产蜜桃av| 日韩欧美一区视频在线观看| 人妻丰满熟妇av一区二区三区 | 人人澡人人妻人| 成人免费观看视频高清| 女性被躁到高潮视频| 精品久久久久久久毛片微露脸| 9191精品国产免费久久| 男女免费视频国产| 国产视频一区二区在线看| 69精品国产乱码久久久| 无遮挡黄片免费观看| 法律面前人人平等表现在哪些方面| 欧美午夜高清在线| 91精品国产国语对白视频| 欧美日韩乱码在线| 免费日韩欧美在线观看| 国产伦人伦偷精品视频| 国产亚洲精品一区二区www | 国产aⅴ精品一区二区三区波| 国产淫语在线视频| 国产精品亚洲av一区麻豆| 久久久久久人人人人人| 别揉我奶头~嗯~啊~动态视频| 少妇粗大呻吟视频| 黄片大片在线免费观看| 美国免费a级毛片| 美女 人体艺术 gogo| 亚洲精品国产区一区二| 久久精品成人免费网站| 中文亚洲av片在线观看爽 | 身体一侧抽搐| 视频在线观看一区二区三区| 黑人操中国人逼视频| 国产亚洲欧美在线一区二区| 黄片播放在线免费| 日本欧美视频一区| 最新在线观看一区二区三区| 在线视频色国产色| 亚洲精品国产色婷婷电影| 19禁男女啪啪无遮挡网站| 一本大道久久a久久精品| 久久精品成人免费网站| 伊人久久大香线蕉亚洲五| 国产单亲对白刺激| 欧美黄色片欧美黄色片| 好看av亚洲va欧美ⅴa在| 午夜福利在线观看吧| 日韩免费av在线播放| 91麻豆av在线| 十八禁网站免费在线| 一本综合久久免费| 中国美女看黄片| 大型黄色视频在线免费观看| 精品午夜福利视频在线观看一区| 亚洲成av片中文字幕在线观看| 精品久久久精品久久久| 国产成人影院久久av| 日韩欧美国产一区二区入口| 亚洲人成电影免费在线| av在线播放免费不卡| xxxhd国产人妻xxx| 亚洲国产精品一区二区三区在线| 999精品在线视频| 国产成人欧美在线观看 | 9191精品国产免费久久| 免费看十八禁软件| 国产在线一区二区三区精| 欧美日韩亚洲国产一区二区在线观看 | a在线观看视频网站| 99久久人妻综合| 亚洲avbb在线观看| 国产一区二区三区综合在线观看| 老司机亚洲免费影院| 国产精品偷伦视频观看了| 涩涩av久久男人的天堂| 亚洲精品国产色婷婷电影| 90打野战视频偷拍视频| 97人妻天天添夜夜摸| 18禁黄网站禁片午夜丰满| 成年动漫av网址| 高潮久久久久久久久久久不卡| 免费女性裸体啪啪无遮挡网站| 建设人人有责人人尽责人人享有的| 国产精品美女特级片免费视频播放器 | 免费日韩欧美在线观看| 香蕉国产在线看| 亚洲美女黄片视频| xxx96com| 91av网站免费观看| 激情视频va一区二区三区| 精品国产一区二区久久| 久热这里只有精品99| 日日爽夜夜爽网站| 天天操日日干夜夜撸| 欧美 日韩 精品 国产| 国产精品美女特级片免费视频播放器 | 亚洲一区中文字幕在线| 欧美人与性动交α欧美精品济南到| 在线视频色国产色| 精品一区二区三区av网在线观看| 免费观看人在逋| 国产视频一区二区在线看| 精品久久久久久电影网| av视频免费观看在线观看| 一级毛片高清免费大全| 国产精品 国内视频| 日韩中文字幕欧美一区二区| 最新在线观看一区二区三区| 亚洲久久久国产精品| 女性被躁到高潮视频| 久99久视频精品免费| 国产精品香港三级国产av潘金莲| 国精品久久久久久国模美| 亚洲一码二码三码区别大吗| 大型黄色视频在线免费观看| 日韩欧美在线二视频 | 激情在线观看视频在线高清 | 久久亚洲精品不卡| 国产99久久九九免费精品| 亚洲av欧美aⅴ国产| 999精品在线视频| 亚洲人成伊人成综合网2020| av线在线观看网站| 99久久精品国产亚洲精品| 好男人电影高清在线观看| 国产色视频综合| 韩国av一区二区三区四区| 国产午夜精品久久久久久| 亚洲情色 制服丝袜| 99热只有精品国产| 精品欧美一区二区三区在线| 亚洲精品一二三| 国产高清国产精品国产三级| 国产不卡一卡二| 欧美另类亚洲清纯唯美| 欧美在线黄色| 午夜老司机福利片| 日本黄色视频三级网站网址 | 激情在线观看视频在线高清 | 动漫黄色视频在线观看| 欧美日韩视频精品一区| av线在线观看网站| 精品午夜福利视频在线观看一区| 在线观看免费视频网站a站| 亚洲欧洲精品一区二区精品久久久| 人人妻人人爽人人添夜夜欢视频| 淫妇啪啪啪对白视频| 日韩熟女老妇一区二区性免费视频| 高清欧美精品videossex| 大香蕉久久成人网| 久久精品国产a三级三级三级| 多毛熟女@视频| 亚洲av成人av| 日韩免费高清中文字幕av| 交换朋友夫妻互换小说| 亚洲中文字幕日韩| 免费在线观看亚洲国产| 精品人妻在线不人妻| 国产aⅴ精品一区二区三区波| 岛国毛片在线播放| 国产精品久久久久成人av| 中国美女看黄片| www.自偷自拍.com| 成人18禁在线播放| 视频区欧美日本亚洲| 777久久人妻少妇嫩草av网站| 在线观看免费午夜福利视频| 一a级毛片在线观看| 啦啦啦在线免费观看视频4| 午夜亚洲福利在线播放| 亚洲精品一卡2卡三卡4卡5卡| 国产色视频综合| 亚洲成人免费av在线播放| 国产高清国产精品国产三级|